Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase IIb randomized, partially blinded, dose-finding trial of TMC278
2004-004055-19Phase 2Completed
- Sponsor
- Tibotec
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rilpivirine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Tibotec. Primary endpoint: Antiviral response at week 48. Started Mar 2005; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-004055-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004055-19.